Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. It develops Apabetalone for diabetes mellitus, chronic kidney, peripheral artery, Orphan, and Alzheimer's diseases. The company was founded by Donald J. McCaffrey and Norman C. W. Wong on August 17, 2000 and is headquartered in Calgary, Canada.